Roexin Pharmaceutical (002793.SZ): Holding subsidiary Shandong Roexin produces and sells inferior drugs, fined 1.8684 million yuan.

Information from the Capital Finance APP, Luoxin Pharmaceutical (002793.SZ) announced that recently, its controlling subsidiary Shandong Luoxin Pharmaceutical Group Co., Ltd. ("Shandong Luoxin") received an "Administrative Penalty Decision" (Lu Drug Supervision Penalty [2026] Y1) issued by the Shandong Provincial Drug Supervision Administration. The injection of azithromycin produced and sold by Shandong Luoxin (batch number: 524053043) was found to be substandard in the drug inspection conducted by the Heilongjiang Provincial Drug Supervision and Inspection Institute in 2025, as the "related substances" did not meet the requirements of the 2020 Chinese Pharmacopoeia Part II, and was deemed "substandard". The Shandong Provincial Drug Supervision Administration has imposed an administrative penalty on Shandong Luoxin, with a total fine of 1.8684 million yuan.